Monitoring cellular immune responses that target the AAV capsid or TGP using ELISpot assays may provide insights into mechanisms that could trigger safety-related events (such as ALT elevations related to liver inflammation) or limit efficacy (decrease in expression) in non-clinical gene therapy studies. Here, GPT is linked to Hepatitis.